This retrospective longitudinal analysis aimed to characterise temporal changes in antimicrobial resistance (AMR) among clinically important bacterial pathogens in Iraq between 2021 and 2024, and to examine implications for empirical antimicrobial therapy and stewardship. The authors used aggregated national AMR surveillance data and interpreted resistance trajectories with respect to empirical treatment options and stewardship strategies.
The analysis comprised 92,338 organism records drawn from the Iraqi national antimicrobial resistance surveillance system. The pathogen breakdown was: Escherichia coli 40,496 records (43.9%), Staphylococcus aureus 24,621 (26.7%), Klebsiella pneumoniae 18,223 (19.7%) and Pseudomonas aeruginosa 8,998 (9.7%). The dataset provided aggregated, de-identified surveillance results only; no patient-level data were accessed by the research team.
Annual resistance proportions were calculated across clinically relevant antimicrobials for each organism. Temporal change was characterised using absolute percentage-point changes across years and by exploratory linear regression models to identify trajectories over the 2021–2024 period. The investigators examined year-to-year variation and applied a false discovery rate correction when assessing statistical significance of temporal trends.
Reported 2024 resistance estimates for selected pathogen–antimicrobial combinations included:
E. coli: ceftriaxone resistance reached 82.9% in 2024; ciprofloxacin resistance was 55.4% in 2024. Amoxicillin–clavulanate resistance declined from 83.5% in 2021 to 57.2% in 2024.
K. pneumoniae: ceftriaxone resistance was 65.2% in 2024 and ciprofloxacin resistance 57.9% in 2024. Meropenem resistance reached 37.4% in 2024.
P. aeruginosa: meropenem resistance reached 62.3% in 2024. Piperacillin–tazobactam resistance declined from 46.4% in 2021 to 32.9% in 2024.
S. aureus: included among the analysed organisms; aggregated totals were reported, but organism-specific year-by-year resistance percentages beyond total counts were not detailed in the abstract.
The report notes several pathogen–antimicrobial combinations exhibited marked year-to-year variation.
Exploratory linear regression was used to characterise resistance trajectories across the study years, and absolute percentage-point changes were calculated to quantify temporal shifts. However, after adjustment for multiple comparisons using a false discovery rate correction, no temporal trend remained statistically significant. This finding highlights heterogeneity and variability in the surveillance estimates across years and antimicrobial agents.
The surveillance results indicate that resistance to several agents central to empirical therapy remains high in Iraq. High levels of resistance to third-generation cephalosporins (for example, ceftriaxone) and fluoroquinolones (ciprofloxacin) among Enterobacterales reduce the reliability of these agents for empirical coverage in settings represented by the national data.
Substantial resistance to meropenem in K. pneumoniae (37.4%) and particularly high meropenem resistance in P. aeruginosa (62.3%) constrain the practical utility of carbapenem escalation when resistance to other β-lactams is suspected. The authors emphasise that heterogeneous resistance trajectories and marked year-to-year variation mean empirical recommendations should not be based solely on single-year national antibiograms. Instead, they support regular integration of national and local resistance surveillance into empirical treatment guidance and antimicrobial stewardship strategies.
The underlying surveillance data analysed are held by the responsible Iraqi national health authorities and are not publicly available due to national data governance and access restrictions. Access may be considered on reasonable request and subject to approval by the relevant authorities and applicable governance requirements.
The study used secondary analysis of de-identified, aggregated national surveillance data supplied by the Department of Clinical Pharmacy, Iraqi Ministry of Health. No patient-level or personally identifiable information was accessed, no additional specimens were collected, and the research team had no contact with patients or modification of clinical care. The authors state that no separate research ethics approval was obtained for this secondary analysis, and that no individual informed consent was required because no identifiable data were available to the research team.
Authors declared no competing interests. The article is a preprint and has not been peer reviewed; the authors and publishers note that the findings should not be used to guide clinical practice without further validation.